Filings & corporate actions
37 results filed
CSVNext results · Q2 FY27
Expected 10 Nov 2026 – 15 Nov 2026
Estimate: filed 41–46 days after quarter end, last 5 times
2026
- 11 AugresultsResults · Q1 FY27 · standalone+0.1%NSE
- 16 JulshareholdingShareholding · 30 Jun 2026-0.6%NSE
- 30 MayresultsResults · Q4 FY26 · standalone-0.8%NSE
- 8 AprshareholdingShareholding · 31 Mar 2026+2.5%NSE
- 13 FebresultsResults · Q3 FY26 · standalone-4.3%NSE
- 8 JanshareholdingShareholding · 31 Dec 2025-3.6%NSE
Reaction to results · all yearsrose on day 0 in 12 of 78 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 11 Aug 2026 | +0.1% | -5.3% | -3.6% | 0.5× |
| Q4 FY26 | 30 May 2026 | -0.8% | +0.6% | -0.4% | 2.0× |
| Q3 FY26 | 13 Feb 2026 | -4.3% | -5.4% | -16.3% | 0.5× |
| Q2 FY26 | 13 Nov 2025 | -0.3% | -3.3% | -14.5% | 0.3× |
| Q1 FY26 | 12 Aug 2025 | -2.9% | -0.4% | +0.9% | 0.9× |
| Q4 FY25 | 30 May 2025 | -1.5% | +6.8% | -4.2% | 0.9× |
| Q3 FY25 | 11 Feb 2025 | +1.4% | -3.3% | -15.6% | 1.4× |
| Q2 FY25 | 15 Nov 2024 | -3.9% | -0.7% | +4.5% | 0.8× |
| Q1 FY25 | 13 Aug 2024 | -1.5% | +6.8% | +4.6% | 0.5× |
| Q4 FY24 | 31 May 2024 | -1.0% | +0.1% | +7.2% | 3.5× |
| Q3 FY24 | 7 Feb 2024 | +5.0% | 0.0% | -9.5% | 0.6× |
| Q2 FY24 | 10 Nov 2023 | +0.2% | 0.0% | +5.9% | 0.2× |
| Q1 FY24 | 14 Aug 2023 | -0.5% | -0.3% | +4.3% | 1.3× |
| Q4 FY23 | 31 May 2023 | -1.2% | -2.5% | -1.9% | 1.7× |
| Q3 FY23 | 15 Feb 2023 | +1.8% | -5.2% | -12.0% | 0.5× |
| Q2 FY23 | 15 Nov 2022 | -2.2% | +3.9% | +1.0% | 0.3× |
| Q1 FY23 | 10 Aug 2022 | -0.3% | -1.6% | +1.1% | 0.7× |
| Q4 FY22 | 31 May 2022 | -0.2% | -1.9% | -10.1% | 0.6× |
| Q3 FY22 | 15 Feb 2022 | -0.7% | -7.4% | -5.3% | 0.5× |
| Q2 FY22 | 13 Nov 2021 | -0.8% | -3.5% | +0.5% | 1.0× |
| Q1 FY22 | 14 Aug 2021 | -1.5% | -12.5% | -6.2% | 0.2× |
| Q4 FY21 | 1 Jul 2021 | +0.5% | +0.1% | +6.1% | 0.5× |
| Q3 FY21 | 13 Feb 2021 | -5.0% | -0.7% | +1.3% | 0.4× |
| Q2 FY21 | 12 Nov 2020 | +5.0% | +40.6% | +139.1% | 0.9× |
| Q1 FY21 | 26 Aug 2020 | -4.9% | -26.1% | +24.8% | 5.8× |
| Q4 FY20 | 1 Jul 2020 | +1.2% | 0.0% | +100.4% | 1.6× |
| Q3 FY20 | 15 Feb 2020 | -4.4% | -21.1% | -33.8% | 0.5× |
| Q2 FY20 | 15 Nov 2019 | +4.6% | +30.6% | +162.0% | 1.4× |
| Q1 FY20 | 14 Aug 2019 | -4.2% | -5.9% | -18.5% | 4.7× |
| Q4 FY19 | 31 May 2019 | 0.0% | +2.1% | -22.9% | 0.9× |
| Q3 FY19 | 26 Feb 2019 | +1.6% | +5.5% | +3.9% | 0.3× |
| Q2 FY19 | 26 Nov 2018 | +0.7% | -2.1% | +5.6% | 1.6× |
| Q1 FY19 | 31 Aug 2018 | +1.0% | 0.0% | -20.1% | 1.3× |
| Q4 FY18 | 23 Jun 2018 | 0.0% | -14.0% | -9.8% | 0.0× |
| Q3 FY18 | 19 Mar 2018 | -1.4% | +0.7% | +6.2% | 0.2× |
| Q2 FY18 | 21 Nov 2017 | -2.7% | -1.6% | -10.1% | 0.1× |
| Q1 FY18 | 18 Aug 2017 | -4.9% | -2.2% | -13.9% | — |
| Q4 FY17 | 17 Jun 2017 | — | — | — | — |
| Q3 FY17 | 17 Feb 2017 | — | — | — | — |
| Q2 FY17 | 22 Nov 2016 | — | — | — | — |
| Q1 FY17 | 13 Aug 2016 | — | — | — | — |
| Q4 FY16 | 1 Jun 2016 | — | — | — | — |
| Q3 FY16 | 14 Feb 2016 | — | — | — | — |
| Q2 FY16 | 13 Nov 2015 | — | — | — | — |
| Q1 FY16 | 16 Aug 2015 | — | — | — | — |
| Q4 FY15 | 2 Jun 2015 | — | — | — | — |
| Q3 FY15 | 20 Feb 2015 | — | — | — | — |
| Q2 FY15 | 20 Nov 2014 | — | — | — | — |
| Q1 FY15 | 20 Aug 2014 | — | — | — | — |
| Q4 FY14 | 11 Jun 2014 | — | — | — | — |
| Q3 FY14 | 15 Feb 2014 | — | — | — | — |
| Q2 FY14 | 11 Dec 2013 | — | — | — | — |
| Q1 FY14 | 23 Aug 2013 | — | — | — | — |
| Q4 FY13 | 2 Jul 2013 | — | — | — | — |
| Q3 FY13 | 21 Feb 2013 | — | — | — | — |
| Q2 FY13 | 19 Nov 2012 | — | — | — | — |
| Q1 FY13 | 23 Aug 2012 | — | — | — | — |
| Q4 FY12 | 30 May 2012 | — | — | — | — |
| Q3 FY12 | 14 Feb 2012 | — | — | — | — |
| Q2 FY12 | 17 Nov 2011 | — | — | — | — |
| Q1 FY12 | 25 Aug 2011 | — | — | — | — |
| Q4 FY11 | 7 Jun 2011 | — | — | — | — |
| Q3 FY11 | 15 Feb 2011 | — | — | — | — |
| Q2 FY11 | 15 Nov 2010 | — | — | — | — |
| Q1 FY11 | 16 Aug 2010 | — | — | — | — |
| Q4 FY10 | 4 Jun 2010 | — | — | — | — |
| Q3 FY10 | 30 Jan 2010 | — | — | — | — |
| Q2 FY10 | 5 Nov 2009 | — | — | — | — |
| Q1 FY10 | 31 Jul 2009 | — | — | — | — |
| Q4 FY09 | 30 Jun 2009 | — | — | — | — |
| Q3 FY09 | 2 Feb 2009 | — | — | — | — |
| Q2 FY09 | 7 Nov 2008 | — | — | — | — |
| Q1 FY09 | 1 Aug 2008 | — | — | — | — |
| Q2 FY08 | 11 Feb 2008 | — | — | — | — |
| Q3 FY08 | 6 Feb 2008 | — | — | — | — |
| Q1 FY08 | 9 Aug 2007 | — | — | — | — |
| Q4 FY07 | 17 Jul 2007 | — | — | — | — |
| Q3 FY07 | 3 Feb 2007 | — | — | — | — |
| Average | -0.8% | -0.8% | +6.8% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+92.0%
Profit YoY-95.5%
Interest cost YoY-95.8%
Revenue QoQ+63.2%
Profit QoQ-48.6%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | -13.7% | +19.4% | +4.0% | -2.4% | +2.0% | +7.6% |
| Profit | -12.6% | -6.8% | -9.8% | -16.6% | -16.1% | -1.2% |
Key data
CSVOpen29.31
Day range29.31 – 30.70
52-week range25.60 – 46.34
From 52w high-35.0%
RSI (14)38.7
ATR (14)1.56
Volume9.1K
Avg volume (20D)54.3K
Rel volume0.17×
Volatility (1Y)52.1%
Turnover₹2.7L
SMA 50 / 20032.20 / 33.05
Delivery percentage
Latest · 6 Oct 202655.7%
20-day avg61.9%
1-year avg63.7%
Percentile (own history)26th
Range15.0–100.0%
Sessions1,729
Over the last 20 sessions BIOFILCHEM settled 61.9% of its traded quantity, which is unusually high for an NSE equity. That is in line with its own one-year average of 63.7%. The latest session ranks higher than 26% of the 1,729 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +1.59% | -4.44% | -5.82% | -10.33% | +9.77% | -27.48% |
Valuation
CSVMarket cap₹49 Cr
P/E (TTM)101.2
EPS (TTM)0.30
Shares outstanding1.63Cr
Listed12 Jun 1996
Ownership
CSVPromoter46.79%
Promoter Δ QoQ0.00 pp
Public53.21%
FII0.00%
DII0.08%
Pledged0.00%
Quarterly results · standalone
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 13.5 | 0.9 | 7.6 | 12.4 |
| YoY chg | +461.3% | -94.0% | -9.4% | +92.0% |
| Net profit (₹ Cr) | 0.1 | 0.1 | 0.2 | 0.1 |
| YoY chg | +242.6% | -51.9% | +6.3% | -95.5% |
| Net margin | 0.6% | 9.2% | 2.8% | 0.9% |
| EPS | 0.05 | 0.05 | 0.13 | 0.07 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 46.79% · public 53.21%2021-062026-06
- Promoter
- Public and others
- Promoter
- 46.79%
- Public
- 53.21%
- Promoter change
- 0.00 pp
- Filed
- 16 Jul 2026
- FII
- 0.00%
- DII
- 0.08%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSVStandalone
₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 17.4 | 5.0 | 15.2 | 8.4 | 2.4 | 14.2 | 8.4 | 6.4 | 13.5 | 0.9 | 7.6 | 12.4 | |
| Other income | 0.0 | 0.0 | 0.4 | 0.0 | 0.0 | 0.0 | 0.2 | 2.8 | 0.1 | 0.1 | 0.1 | 0.1 | |
| Total income | 17.4 | 5.1 | 15.6 | 8.5 | 2.4 | 14.2 | 8.6 | 9.3 | 13.6 | 0.9 | 7.7 | 12.4 | |
| Total expenses | 17.2 | 4.9 | 15.3 | 8.2 | 2.4 | 14.0 | 8.3 | 6.5 | 13.5 | 0.8 | 7.2 | 12.3 | |
| └ Finance costs | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| └ Depreciation | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
| Profit before tax | 0.2 | 0.1 | 0.3 | 0.2 | 0.0 | 0.2 | 0.3 | 2.8 | 0.1 | 0.1 | 0.5 | 0.1 | |
| Tax expense | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 0.1 | 0.4 | 0.0 | 0.0 | 0.3 | 0.0 | |
| Net profit | 0.1 | 0.1 | 0.2 | 0.2 | 0.0 | 0.2 | 0.2 | 2.4 | 0.1 | 0.1 | 0.2 | 0.1 | |
| EPS | 0.08 | 0.06 | 0.15 | 0.10 | 0.01 | 0.10 | 0.12 | 1.48 | 0.05 | 0.05 | 0.13 | 0.07 | |
| Net margin | 0.71% | 1.85% | 1.64% | 2.01% | 1.01% | 1.16% | 2.39% | 37.48% | 0.62% | 9.25% | 2.80% | 0.88% | |
| PBT margin | 0.88% | 2.25% | 1.81% | 2.70% | 1.36% | 1.56% | 3.04% | 42.95% | 0.82% | 12.46% | 6.20% | 1.09% | |
| Tax rate | 19.62% | 17.65% | 9.50% | 25.75% | 25.61% | 25.77% | 21.36% | 12.72% | 25.16% | 25.77% | 54.74% | 18.64% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 11 Aug 2026.
BIOFILCHEM at a glance
- BIOFILCHEM closed at ₹30.11 on 6 Oct 2026, +1.59% on the day, -27.5% over one year, 35.0% below its 52-week high of ₹46.34.
- Delivery was 55.7% of traded quantity on 6 Oct 2026, the 26th percentile of its own 1,729 sessions with a reading (20-session average 61.9%, 1-year average 63.7%).
- Market capitalisation is ₹49 crore at a trailing P/E of 101.2 (trailing EPS ₹0.3).
- Q1 FY27 results (standalone, filed 11 Aug 2026): revenue ₹12 crore (+92.0% year on year), net profit ₹0 crore (-95.5%); the price moved +0.1% on the first session after.
- Promoters held 46.79% at 30 Jun 2026, unchanged on the previous filing.
- Q2 FY27 results are expected between 10 Nov 2026 and 15 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE829A01014
SeriesEQ
Listed12 Jun 1996
History from27 Jul 2017
Sessions2,260
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE